pharma · Carcinoma, Non-small-cell Lung · Type 2 Diabetes Mellitus · LGND
LIGAND PHARMACEUTICALS
LIGAND PHARMACEUTICALS INC
LIGAND PHARMACEUTICALS clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US
- Founded
- 1987
- Employees
- 130
- Programs
- 34
- Drugs
- 25
- Patents
- 133
LIGAND PHARMACEUTICALS projects
7 ClinicalTrials.gov programs sponsored by LIGAND PHARMACEUTICALS.
LIGAND PHARMACEUTICALS has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Bexarotene (Targretin®)
LIGAND PHARMACEUTICALS INC
Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
1 trial -
LGD-6972
LIGAND PHARMACEUTICALS INC
Type 2 Diabetes Mellitus
2 trials -
LGD-6972 Solution
LIGAND PHARMACEUTICALS INC
Type 2 Diabetes Mellitus (T2DM)
1 trial -
NCO-48 Fumarate
LIGAND PHARMACEUTICALS INC
Hepatitis B
1 trial -
NCO-48 Fumarate 4 mg
LIGAND PHARMACEUTICALS INC
Chronic Hepatitis B
1 trial -
Ramipril tablet 10 mg
LIGAND PHARMACEUTICALS INC
Bioequivalence
1 trial -
Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg
LIGAND PHARMACEUTICALS INC
Bioequivalence
1 trial
Frequently asked questions
How many clinical projects does LIGAND PHARMACEUTICALS have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.